ARL13B is regulated by the ERK/P90 pathway and mediates TMZ resistance in glioblastoma via microvesicles
Haichao Xing, Ying Chen, Haolin Li, Mingjie Wang, Yujing Cao, Xiaomin Liu · 2026
Read ARL13B is regulated by the ERK/P90 pathway and mediates TMZ resistance in glioblastoma via microvesicles by Haichao Xing, Ying Chen, Haolin Li, Mingjie Wang, Yujing Cao, Xiaomin Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13562529.txt.
Description
Haichao Xing and five colleagues uncover a route by which brain tumours pump out the main drug used against them. Temozolomide often fails in glioblastoma, and high levels of a protein called ARL13B mark patients at greater risk. Working from public tumour datasets and lab experiments, the 2026 team traced how the protein is controlled and what it does. A signalling pathway known as ERK/P90 switches the gene on, with a factor named C/EBPβ doing the direct work at its start site.
Once active, ARL13B made tumour cells shed more tiny vesicles from their surface, and those vesicles carried drug out with them. Less drug stayed inside the cells, so treatment weakened. Blocking the ERK/P90 pathway restored the drug's effect in the experiments. The authors nominate both the pathway and ARL13B itself as targets that could rescue a standard therapy many patients currently fail.
Catalog record
| CREATOR | Haichao Xing, Ying Chen, Haolin Li, Mingjie Wang, Yujing Cao, Xiaomin Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39403 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |